ATE130873T1 - Nachweis der expression von neu genen und produkten. - Google Patents
Nachweis der expression von neu genen und produkten.Info
- Publication number
- ATE130873T1 ATE130873T1 AT89905846T AT89905846T ATE130873T1 AT E130873 T1 ATE130873 T1 AT E130873T1 AT 89905846 T AT89905846 T AT 89905846T AT 89905846 T AT89905846 T AT 89905846T AT E130873 T1 ATE130873 T1 AT E130873T1
- Authority
- AT
- Austria
- Prior art keywords
- oncogenes
- neu
- proof
- expression
- products
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 abstract 2
- 108700020796 Oncogene Proteins 0.000 abstract 2
- 102000043276 Oncogene Human genes 0.000 abstract 2
- 108700020978 Proto-Oncogene Proteins 0.000 abstract 2
- 102000052575 Proto-Oncogene Human genes 0.000 abstract 2
- 108700020302 erbB-2 Genes Proteins 0.000 abstract 2
- 239000002853 nucleic acid probe Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000869 mutational effect Effects 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18250188A | 1988-04-18 | 1988-04-18 | |
| US29718889A | 1989-01-13 | 1989-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE130873T1 true ATE130873T1 (de) | 1995-12-15 |
Family
ID=26878143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT89905846T ATE130873T1 (de) | 1988-04-18 | 1989-04-18 | Nachweis der expression von neu genen und produkten. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0412116B1 (de) |
| JP (3) | JPH03505964A (de) |
| KR (1) | KR900700625A (de) |
| AT (1) | ATE130873T1 (de) |
| AU (1) | AU3568289A (de) |
| CA (1) | CA1341191C (de) |
| DE (1) | DE68924979T2 (de) |
| WO (1) | WO1989010412A1 (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| WO1990014357A1 (en) * | 1989-05-19 | 1990-11-29 | Genentech, Inc. | Her2 extracellular domain |
| US6884418B1 (en) | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
| US7282345B1 (en) | 1989-08-04 | 2007-10-16 | Schering Ag | C-erbB-2 external domain: GP75 |
| EP0494135B1 (de) * | 1989-09-29 | 1996-04-10 | Oncogene Science, Inc. | p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen |
| US6673559B1 (en) | 1989-12-27 | 2004-01-06 | The Government Of The United States Of America As Represented By The Department Of Health And Human Services | Met proto-oncogene and a method for predicting breast cancer progression |
| US5348864A (en) * | 1991-01-25 | 1994-09-20 | E. R. Squibb & Sons, Inc. | Mouse vav proto-oncogene DNA and protein sequences |
| US5468634A (en) * | 1991-06-24 | 1995-11-21 | The University Of North Carolina At Chapel Hill | Axl oncogene |
| US5939531A (en) * | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
| WO1993021319A1 (en) * | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
| AU4645293A (en) * | 1992-06-26 | 1994-01-24 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | The met proto-oncogene and a method for predicting breast cancer progression |
| US5783404A (en) * | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| US6709858B1 (en) * | 1997-11-03 | 2004-03-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof |
| US7098191B2 (en) | 1997-11-03 | 2006-08-29 | The Arizona Board Of Reagents | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US20010023241A1 (en) | 1998-02-04 | 2001-09-20 | Sliwkowski Mark X. | Use of heregulin as a growth factor |
| US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
| US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
| US7396810B1 (en) | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| EP1282443B1 (de) | 2000-05-19 | 2009-09-02 | Genentech, Inc. | Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb-antagonisten |
| US20030188326A1 (en) | 2000-11-03 | 2003-10-02 | Dana Farber Cancer Institute | Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof |
| ES2329565T3 (es) | 2002-03-01 | 2009-11-27 | Siemens Healthcare Diagnostics Inc. | Pruebas para monitorear pacientes con cancer, basadas en los niveles de analito de dominio extracelular (ecd) del factor receptor del crecimiento epidermico (egfr),solo o en combinacion con otros analitos,en muestras de fluidos corporales. |
| TWI441646B (zh) | 2005-01-21 | 2014-06-21 | Genentech Inc | 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途 |
| CA2596133C (en) | 2005-02-23 | 2016-11-15 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| PL2132573T3 (pl) | 2007-03-02 | 2014-09-30 | Genentech Inc | Prognozowanie odpowiedzi na inhibitor dimeryzacji HER oparte na niskiej ekspresji HER3 |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| EP2171090B1 (de) | 2007-06-08 | 2013-04-03 | Genentech, Inc. | Genexpressionsmarker für tumorresistenz gegen behandlung mit her2-inhibitor |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
| EP2435071A1 (de) | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulatoren für den her2-signalweg bei her2-exprimierenden patienten mit magenkrebs |
| JP5981853B2 (ja) | 2010-02-18 | 2016-08-31 | ジェネンテック， インコーポレイテッド | ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用 |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
| EP2655413B1 (de) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung |
| US20140363438A1 (en) | 2011-08-17 | 2014-12-11 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
| WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
| AU2012346540C1 (en) | 2011-11-30 | 2019-07-04 | Genentech, Inc. | ErbB3 mutations in cancer |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| MX2014011500A (es) | 2012-03-27 | 2014-12-05 | Genentech Inc | Diagnosticos y tratamientos relacionados a inhibidores her3. |
| RU2692773C2 (ru) | 2012-11-30 | 2019-06-27 | Ф.Хоффманн-Ля Рош Аг | Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1 |
| WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
| AU2020272664A1 (en) | 2019-04-08 | 2021-11-04 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| US12370217B2 (en) | 2019-05-14 | 2025-07-29 | Htyr Acquisition Llc | Compositions and methods for treating T cell exhaustion |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935341A (en) * | 1986-06-04 | 1990-06-19 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
| IE56509B1 (en) * | 1982-11-04 | 1991-08-28 | Univ California | Methods for oncogenic detection |
-
1989
- 1989-04-18 JP JP1505853A patent/JPH03505964A/ja active Pending
- 1989-04-18 AT AT89905846T patent/ATE130873T1/de not_active IP Right Cessation
- 1989-04-18 CA CA000597017A patent/CA1341191C/en not_active Expired - Lifetime
- 1989-04-18 WO PCT/US1989/001636 patent/WO1989010412A1/en not_active Ceased
- 1989-04-18 EP EP89905846A patent/EP0412116B1/de not_active Expired - Lifetime
- 1989-04-18 AU AU35682/89A patent/AU3568289A/en not_active Abandoned
- 1989-04-18 DE DE68924979T patent/DE68924979T2/de not_active Expired - Lifetime
- 1989-12-15 KR KR1019890702361A patent/KR900700625A/ko not_active Withdrawn
-
1999
- 1999-12-08 JP JP11376423A patent/JP2000175692A/ja active Pending
-
2003
- 2003-08-18 JP JP2003294484A patent/JP2004043486A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03505964A (ja) | 1991-12-26 |
| EP0412116A1 (de) | 1991-02-13 |
| DE68924979T2 (de) | 1996-10-24 |
| JP2000175692A (ja) | 2000-06-27 |
| JP2004043486A (ja) | 2004-02-12 |
| EP0412116B1 (de) | 1995-11-29 |
| AU3568289A (en) | 1989-11-24 |
| DE68924979D1 (de) | 1996-01-11 |
| CA1341191C (en) | 2001-02-27 |
| KR900700625A (ko) | 1990-08-16 |
| WO1989010412A1 (en) | 1989-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE130873T1 (de) | Nachweis der expression von neu genen und produkten. | |
| WO1987007646A3 (en) | Detection of point mutations in neu genes | |
| Rachkovsky et al. | Melanoma× macrophage hybrids with enhanced metastatic potential | |
| Jones et al. | In vitro correlates of transformation in C3H/10T½ clone 8 mouse cells | |
| Wickner et al. | Deoxyribonucleic Acid Polymerase II of Escherichia coli: I. THE PURIFICATION AND CHARACTERIZATION OF THE ENZYME | |
| IL84866A0 (en) | Method for detecting tumors | |
| FI875082A0 (fi) | Dna-sekvensser deriverade fraon genom av papillomavirus, deras anvaendning foer in vitro diagnostiska aendamaol; samt framstaellning av antigeniska kompositioner. | |
| ES8704005A1 (es) | Un metodo para evaluar la probabilidad de malignidad celular en una muestra biologica de un haspedante humano. | |
| GB1340366A (en) | Fluid analysis apparatus | |
| ATE397097T1 (de) | Nachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests | |
| ATE140488T1 (de) | Genetischer test für zytochrom-p450 | |
| ATE125872T1 (de) | Nachweis von campylobacter. | |
| Heard et al. | Electrophoretic mobility of cultured mesodermal tissue cells | |
| Wilkins | DNA repair: a simple enzymatic assay for human cells | |
| EP0128018A3 (en) | Molecular genetic probe, and method of forming same, assay technique and kit using said molecular genetic probe | |
| GB1466828A (en) | Diagnostic test system | |
| Yoshida et al. | DNA polymerase associated with nuclear membrane of calf thymus | |
| DE68926658D1 (de) | Diagnostische gene zum nachweis von toxoplasmose | |
| Nash | Purification of Bacteriophage λ, Int Protein | |
| DE69940770D1 (de) | Vervielfältigung und nachweis von ebv barf1 zur diagnose von nasopharyngealen karzinom | |
| SE9500030L (sv) | Förfarande för bestämning av metastatisk potentialhos tumörceller | |
| FI862869A0 (fi) | Oeverdragna fasta kroppar foer bindande av aemnen med biologisk affinitet, deras framstaellningsfoerfarande och deras anvaendning. | |
| WO1990000607A3 (en) | Gap gene sequences and diagnostic uses thereof | |
| Marshall et al. | Isoenzymes of hexokinase, 6-phosphogluconate dehydrogenase, phosphoglucomutase and lactate dehydrogenase in uterine cancer | |
| Viola et al. | Differences in murine leukaemia virus-specific DNA sequences in normal and malignant cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |